A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification.
about
Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune TherapyZYG11A serves as an oncogene in non-small cell lung cancer and influences CCNE1 expressionInhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth.Molecular characterization of a selected cohort of patients affected by pulmonary metastases of malignant melanoma: Hints from BRAF, NRAS and EGFR evaluation.Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome.Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125bTranslation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma.Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cellsHighlights on mechanisms of drugs targeting MDSCs: providing a novel perspective on cancer treatment.P21-activated kinase 1 regulates resistance to BRAF inhibition in human cancer cells.Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies.Detrimental effects of melanocortin-1 receptor (MC1R) variants on the clinical outcomes of BRAF V600 metastatic melanoma patients treated with BRAF inhibitors.Axl in ovarian cancer: a step forward for clinical breakthrough?HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma.
P2860
Q26783032-23B9E14D-6E4C-4CE1-85F6-45692C98616AQ28602015-9DDCD268-A262-4F0C-A90F-4D15C358BB60Q35746524-389FB617-B9FD-43EA-B444-7934789F71F1Q36260662-A6938899-2AB4-449E-975B-0F086D8F1107Q36544445-1DD2BEE3-AF18-4131-9E80-C55F42BF5F72Q36782461-A52D989D-5C83-46C9-9BD0-38650719479BQ37618946-12E178FA-740E-4ABF-A8D8-3416D013EFBCQ37736262-3B8796B7-10F4-46C8-AEB4-FE369B4860F4Q38398117-76CF5BF3-0456-4346-8973-3F9027080113Q38722990-B773011A-3426-4B6E-B1D1-FF18990374D3Q39157476-19605304-A9B3-4BB4-AF99-49CE87F92F95Q39474116-E53FE855-F619-4951-B92F-166E4E71B4D5Q42316735-6CFD6242-12E3-48DA-8827-C7313C2EE125Q47325071-66766E94-9276-473B-99FB-ACCACBEFDC0F
P2860
A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
A melanoma subtype with intrin ...... es gene-driven classification.
@en
type
label
A melanoma subtype with intrin ...... es gene-driven classification.
@en
prefLabel
A melanoma subtype with intrin ...... es gene-driven classification.
@en
P2093
P2860
P356
P1433
P1476
A melanoma subtype with intrin ...... ses gene-driven classification
@en
P2093
Antonella Tomassetti
Filippo De Braud
Gabriella Nicolini
Gabrina Tragni
Ilaria Bersani
Matteo Dugo
Michele Del Vecchio
Silvana Canevari
Valentina Colonna
P2860
P304
P356
10.18632/ONCOTARGET.3007
P407
P577
2015-03-01T00:00:00Z